Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
MedImmune LLC |
---|---|
Information provided by: | MedImmune LLC |
ClinicalTrials.gov Identifier: | NCT00105313 |
For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507.
For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.
Condition | Intervention | Phase |
---|---|---|
Lymphoma Leukemia Cancer |
Drug: MEDI-507 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Individuals may be eligible for this study if they are 18 years of age or older and:
United States, California | |
USC/Norris Cancer Center | |
Los Angeles, California, United States, 90033 | |
United States, Connecticut | |
Yale Cancer Center | |
New Haven, Connecticut, United States, 06520 | |
United States, District of Columbia | |
Georgetown University Medical Center, Lombardi Comprehensive Cancer Center | |
Washington, District of Columbia, United States, 20007 | |
United States, Florida | |
H. Lee Moffitt Cancer Ctr & Research Institute Div of Hem/Onc | |
Tampa, Florida, United States, 33612 | |
United States, Maryland | |
University of Maryland School of Medicine, Greenebaum Cancer Center | |
Baltimore, Maryland, United States, 21201 | |
United States, Massachusetts | |
Tufts New England Medical Center | |
Boston, Massachusetts, United States, 02111 | |
United States, Missouri | |
Washington University | |
St. Louis, Missouri, United States, 63110 | |
United States, Nevada | |
Nevada Cancer Institute | |
Las Vegas, Nevada, United States, 89135 | |
United States, North Carolina | |
Wake Forest University Health Sciences | |
Winston-Salem, North Carolina, United States, 27517 | |
United States, Pennsylvania | |
Kimmel Cancer Center, Thomas Jefferson University | |
Philadelphia, Pennsylvania, United States, 19107 | |
United States, Texas | |
M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Study Director: | Luz Hammershaimb, MD | MedImmune LLC |
Study ID Numbers: | MI-CP107 |
Study First Received: | March 11, 2005 |
Last Updated: | June 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00105313 |
Health Authority: | United States: Food and Drug Administration |
Lymphatic Diseases Leukemia Immunoproliferative Disorders Lymphoproliferative Disorders Lymphoma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |